Home » GLAXOSMITHKLINE AND ADOLOR ANNOUNCE THE COMPLETION OF ENROLLMENT OF PIVOTAL CLINICAL STUDIES OF ENTEREG
GLAXOSMITHKLINE AND ADOLOR ANNOUNCE THE COMPLETION OF ENROLLMENT OF PIVOTAL CLINICAL STUDIES OF ENTEREG
GlaxoSmithKline and Adolor Corporation announced today that GSK has completed
enrollment of the Phase 3 clinical program to evaluate the efficacy and safety
of the oral investigational drug Entereg (alvimopan) for the treatment of gastrointestinal
adverse events caused by opioids used for persistent non-cancer pain.
Genetic
Engineering News
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May